RxDoctor Payments DataLook up a doctor →

Melanie Rosenblatt, MD

Pain Medicine · Boca Raton, FLNPI 1730192758

Payments from drug & device makers

$64,828in general payments, 2019–2025

Across 323 payments — averaging $200.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$34K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$11K
  • MDD US Operations, LLC$7K
  • Medtronic$3K
  • Abbott$2K
  • Boston Scientific$1K
  • plus $7K from 37 others

What the payments were for

  • Consulting fees$11,47518%
  • Speaking & faculty fees$34,10053%
  • Travel & lodging$8,53213%
  • Food & beverage$10,72117%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,828 in reported general payments places this provider in the 95th percentile of 596 pain medicine providers in Florida.

See all pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$256,747
Medicare patients
280
Services billed
6,919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl263$208,655
NucyntaTapentadol Hcl153$96,313
Nucynta ErTapentadol Hcl103$79,158
Buprenorphine207$69,439
Xtampza ErOxycodone Myristate46$15,536
Tramadol Hcl ErTramadol Hcl249$14,171
ZubsolvBuprenorphine Hcl/Naloxone Hcl13$11,364
SuboxoneBuprenorphine Hcl/Naloxone Hcl24$10,272
ButransBuprenorphine19$9,917
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl73$6,513
Morphine Sulfate199$4,396
Gabapentin233$3,409
Pregabalin209$3,317
Tizanidine Hcl270$2,826
Morphine Sulfate ErMorphine Sulfate142$2,726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta, Nucynta Er, Xtampza Er$765$399,662565 claims
Orexo US, Inc.Zubsolv$157$11,36413 claims
Indivior Inc.Suboxone$287$10,27224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 596 pain medicine providers in Florida.

Other pain medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →